Search

Amrubicin

In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006.

CZEN 002

It appears that CZEN-002 works on a receptor in yeast that has yet to be identified. … The antimicrobial activity of CZEN-002 is unique in that it does not depend on direct damage to the microbial membrane.

Penicillium glaucum

Penicillium glaucum allergenic extract is used in allergenic testing.

Alaproclate

Development was discontinued due to concerns over hepatotoxicity observed in animal studies. … Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s.

Leptin

Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. … Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite

CERE-110

CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system.

Cobaltous sulfate

Osemozotan

MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)

Pridinol

Bithionol

Bithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders. … Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)).